scholarly journals Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphism and Left Ventricular Function in Early Chronic Kidney Disease

PLoS ONE ◽  
2015 ◽  
Vol 10 (1) ◽  
pp. e0116160 ◽  
Author(s):  
Sourabh Chand ◽  
Colin D. Chue ◽  
Nicola C. Edwards ◽  
James Hodson ◽  
Matthew J. Simmonds ◽  
...  
Stroke ◽  
2003 ◽  
Vol 34 (11) ◽  
pp. 2555-2559 ◽  
Author(s):  
Vini G. Khurana ◽  
Youvraj R. Sohni ◽  
Wells I. Mangrum ◽  
Robyn L. McClelland ◽  
Dennis J. O’Kane ◽  
...  

2005 ◽  
Vol 102 (1) ◽  
pp. 68-71 ◽  
Author(s):  
Hiroyuki Akagawa ◽  
Hidetoshi Kasuya ◽  
Hideaki Onda ◽  
Taku Yoneyama ◽  
Atsushi Sasahara ◽  
...  

Object. Among patients with aneurysms, those with heterozygous (T/C) endothelial nitric oxide synthase (eNOS) T-786C single nucleotide polymorphism (SNP), a mutation reducing endothelial nitric oxide synthesis, are reported to have larger ruptured intracranial aneurysms (IAs) than those with homozygous (C/C or T/T) genotype. The authors tested patients harboring aneurysms for eNOS T-786C SNP in two populations—Japanese and Korean. Methods. The eNOS T-786C SNP was genotyped through direct sequencing in genomic DNA obtained from 336 Japanese and 191 Korean patients with IAs and 214 Japanese and 191 Korean control volunteers. Differences in genotype frequencies among the various aneurysm sizes were evaluated using the Fisher exact test. There was no significant difference in heterozygous (T/C) eNOS T-786C SNP between aneurysms 5 mm or smaller and those from 6 to 9 mm, and between lesions 5 mm or smaller and those 10 mm or larger in 336 Japanese patients harboring aneurysms—220 with ruptured and 116 with unruptured lesions—and in 191 Korean patients with ruptured aneurysms. Conclusion. The eNOS T-786C SNP genotype does not influence the size of aneurysms.


2019 ◽  
Vol 317 (2) ◽  
pp. F275-F285 ◽  
Author(s):  
Isabel Amador-Martínez ◽  
Rosalba Pérez-Villalva ◽  
Norma Uribe ◽  
César Cortés-González ◽  
Norma A. Bobadilla ◽  
...  

Major cardiovascular events are a common complication in patients with chronic kidney disease (CKD). Endothelial dysfunction can contribute to the cardiovascular injury observed in CKD. Here, we used a rat model of acute kidney injury to CKD transition to investigate heart alterations in the pathway activating endothelial nitric oxide synthase (eNOS) and its impact on the cardiac injury observed during CKD progression. Fifty male Wistar rats were subjected to sham surgery ( n = 25) or bilateral renal ischemia-reperfusion (IR-CKD) for 45 min ( n = 25). Rats were studied on a monthly basis up to 5 mo ( n = 5). In another set of sham and IR-CKD rats, l-arginine was administered starting on the third month after renal ischemia. CKD development and cardiac alterations were monitored in all groups. CKD was characterized by a progressive increase in proteinuria and renal dysfunction that was evident after the fifth month of followup. Heart hypertrophy was observed starting on the fourth month after ischemia-reperfusion. There was a significant increase in brain natriuretic peptide levels. In the heart, IR-CKD rats had increased eNOS phosphorylation at threonine 495 and reduced eNOS-heat shock protein-90α interactions. l-Arginine administration prevented the heart alterations observed during CKD and increased eNOS coupling/dimerization and activation. In summary, CKD progression is accompanied by cardiac hypertrophy, fibrosis, oxidative stress, and increased brain natriuretic peptide levels. These alterations were associated with limited eNOS activation in the heart, which may result in reduced nitric oxide bioavailability and contribute to cardiac injury during CKD.


2010 ◽  
Vol 85 (9) ◽  
pp. 814-820 ◽  
Author(s):  
Kiran Bambha ◽  
W. Ray Kim ◽  
Charles B. Rosen ◽  
Rachel A. Pedersen ◽  
Cynthia Rys ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document